Table 3 Association between VEGF and eNOS polymorphisms and overall survival (OS)
Polymorphisms | CT + B | CT | ||||
|---|---|---|---|---|---|---|
Median OS (95% CI) | HR (95% CI) | P* | Median OS (95% CI) | HR (95% CI) | P* | |
VEGF −2578 | ||||||
AA | 26.1 (9.0–34.5) | 1.05 (0.61–1.81) | 24.0 (14.4–36.7) | 1.11 (0.67–1.85) | ||
CC/CA | 21.4 (19.3–27.2) | 1.00 | 0.854 | 20.8 (19.2–24.5) | 1.00 | 0.671 |
VEGF −1498 | ||||||
CC | 26.1 (10.4–33.1) | 1.12 (0.66–1.91) | 26.6 (14.4–36.7) | 0.95 (0.56–1.59) | ||
TT/CT | 21.8 (19.3-27.2) | 1.00 | 0.664 | 20.8 (18.8–24.3) | 1.00 | 0.834 |
VEGF −1154 | ||||||
AA | 21.8 (2.3–30.4) | 1.18 (0.53–2.63) | 20.2 (11.1–29.2) | 1.92 (0.96–3.85) | ||
GA/GG | 21.4 (14.6–28.8) | 1.00 | 0.686 | 25.2 (19.2–29.1) | 1.00 | 0.066 |
VEGF −634 | ||||||
GC | 19.3 (13.1–22.0) | 1.54 (0.98–2.44) | 20.2 (16.8–24.3) | 1.18 (0.76–1.82) | ||
GG/CC | 29.1 (20.9–33.5) | 1.00 | 0.064 | 24.3 (20.2–29.2) | 1.00 | 0.456 |
VEGF +936 | ||||||
TT | 8.6 (7.9–13.9) | 5.48 (1.60–18.8) | 28.0 (–) | 0.96 (0.11–7.98) | ||
CT/CC | 22.7 (20.5–27.5) | 1.00 | 0.007 | 21.3 (19.2–25.2) | 1.00 | 0.967 |
eNOS +894 | ||||||
GT | 20.1 (12.0–23.2) | 1.80 (1.12–2.89) | 24.3 (17.9–28.6) | 0.82 (0.53–1.25) | ||
GG/TT | 26.1 (21.0–33.5) | 1.00 | 0.014 | 21.3 (19.2–26.4) | 1.00 | 0.356 |
eNOS VNTR | ||||||
4bb | 24.8 (20.1–34.5) | 0.54 (0.33–0.89) | 23.6 (19.9–28.0) | 0.76 (0.46–1.23) | ||
4ab/4aa | 20.6 (13.7–24.7) | 1.00 | 0.015 | 20.1 (15.0–23.3) | 1.00 | 0.259 |
eNOS −786 | ||||||
CC | 27.2 (14.6–33.5) | 0.97 (0.53–1.80) | 20.4 (16.0–21.7) | 1.40 (0.77–2.55) | ||
CT/TT | 21.3 (16.4–27.4) | 1.00 | 0.931 | 23.6 (19.9–28.0) | 1.00 | 0.270 |